(a) Representative spider plots showing tumor growth in
WT mice s.c. engrafted with
MC38-B2m−/− tumors treated
with PBS, anti-PD-1+anti-CTLA-4, or IL-18 or DR-18. (b)
Kaplan-Meier survival curves and (c) representative spider
plots of WT mice s.c. engrafted with
YUMMER1.7-B2m−/− tumors
treated twice weekly with PBS, anti-PD-1+anti-CTLA-4, IL-18, DR-18, or DR-18
plus anti-CD8 and anti-NK1.1 antibodies. Depleting antibodies were given the
same schedule as MC38-B2m−/− (see
methods). (d)
Kaplan-Meier survival curves and (e) spider plots showing tumor
growth of WT mice s.c. engrafted with 1×106 RMA-S tumor
cells and treated with PBS, anti-PD-1, IL-18, DR-18 or DR-18+ anti-NK1.1.
Spider plot. (a-e) Data is representative of 2 independent
experiments and survival curve data are pooled from 2 independent
experiments. (f) Absolute cell number of intratumoral NK cells
(NK1.1+CD3−Eomes+DX5+CD200R−),
NKT cells (NK1.1+CD3+) and ILC1 cells
(NK1.1+CD3−Eomes−DX5−CD200R+)
in WT mice s.c engrafted with
MC38-B2m−/− tumors in
indicated treatment groups. (g) t-SNE projection of different
clusters in YUMMER1.7-B2m−/−
tumors as a function of treatment. YUMMER1.7 tumors are shown in light grey
(discussed in Fig. 3, see
methods). (h)
Representative flow cytometry plots of IFNγ and Ki67 staining on
intratumoral NK cells from
YUMMER1.7-B2m−/− tumors
treated with PBS or DR-18. (i,j) Frequency of
Ki67+IFNγ+ NK cells from
YUMMER1.7-B2m−/−
(i) and MC38-B2m−/−
(j) tumors treated with PBS or DR-18. (k)
Representative mean tumor growth of WT mice s.c. engrafted with
MC38-B2m−/− tumors and
treated with PBS, DR-18, or DR-18 plus anti-FasL or anti-IFN-γ.
(l) Representative mean tumor growth of
Perforin−/− mice s.c.
engrafted with MC38-B2m−/− tumors
and treated with PBS (n=3) and DR-18 (n=5) as indicated. (h-l)
Data are representative of 2 independent experiments with 5 mice per group.
P values were calculated using two-tailed unpaired Student’s t-test,
and data are presented as the mean ± SEM.